In this study, we demonstrate the anti-leukemic activity of the selective WEE1 kinase inhibitor adavosertib in a large majority of high-risk and relapsed ALL specimens, independent of TP53 mutation status. Here, TP53 is linked to acute lymphoblastic leukemia.